PriceTargets.com logo

Rain Oncology - RAIN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.44
  • Forecasted Upside: 88.15%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$8.74 As of 03/31/2023 01:00 AM ET
▼ -0.03 (-0.34%)

This chart shows the closing price for RAIN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rain Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RAIN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RAIN

Analyst Price Target is $16.44
▲ +88.15% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Rain Oncology in the last 3 months. The average price target is $16.44, with a high forecast of $24.00 and a low forecast of $11.00. The average price target represents a 88.15% upside from the last price of $8.74.

This chart shows the closing price for RAIN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Rain Oncology.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2023SVB LeerinkReiterated RatingOutperform$11.00Low
3/21/2023SVB SecuritiesInitiated CoverageOutperform$11.00Low
3/16/2023CitigroupLower Target$29.00 ➝ $24.00Low
3/13/2023MizuhoLower TargetBuy$18.00 ➝ $17.00Low
3/10/2023EF Hutton Acquisition Co. IReiterated RatingBuy$16.00Low
3/10/2023HC WainwrightBoost TargetBuy$12.00 ➝ $19.00Low
2/10/2023MizuhoReiterated RatingBuy$18.00Low
2/9/2023EF Hutton Acquisition Co. IReiterated RatingBuy$16.00Low
1/31/2023Roth CapitalReiterated RatingBuy$21.00Low
1/23/2023MizuhoInitiated CoverageBuy$18.00Low
1/6/2023Lifesci CapitalReiterated RatingOutperformLow
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$16.00Low
11/23/2022CitigroupLower TargetBuy$30.00 ➝ $29.00Low
11/11/2022HC WainwrightBoost Target$10.00 ➝ $12.00Low
9/12/2022HC WainwrightInitiated CoverageBuy$10.00Low
6/23/2022JonestradingInitiated CoverageBuy$17.00Low
6/2/2022Roth CapitalInitiated CoverageBuy$16.00High
5/27/2022Piper SandlerLower Target$26.00 ➝ $12.00Low
3/31/2022OppenheimerInitiated CoverageOutperform$15.00High
1/3/2022GuggenheimLower Target$26.00 ➝ $20.00High
11/10/2021Piper SandlerBoost TargetOverweight$25.00 ➝ $26.00High
9/14/2021The Goldman Sachs GroupDowngradeHold$22.00Low
7/20/2021Piper SandlerReiterated RatingOverweight$25.00Low
5/18/2021CitigroupInitiated CoverageBuyHigh
5/18/2021GuggenheimInitiated CoverageBuy$26.00High
5/18/2021Piper SandlerInitiated CoverageOverweight$25.00High
5/18/2021The Goldman Sachs GroupInitiated CoverageBuy$56.00High
(Data available from 4/1/2018 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/3/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/3/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2022
  • 8 very positive mentions
  • 7 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
Mentions as of
12/2/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/31/2023
  • 2 very positive mentions
  • 10 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
3/2/2023
  • 5 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 5 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Rain Oncology logo
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Read More

Today's Range

Now: $8.74
Low: $8.64
High: $9.10

50 Day Range

MA: $9.10
Low: $7.77
High: $10.83

52 Week Range

Now: $8.74
Low: $2.15
High: $14.48

Volume

76,591 shs

Average Volume

194,563 shs

Market Capitalization

$317.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Rain Oncology?

The following Wall Street sell-side analysts have issued stock ratings on Rain Oncology in the last twelve months: Citigroup Inc., EF Hutton Acquisition Co. I, HC Wainwright, Jonestrading, Lifesci Capital, Mizuho, Piper Sandler, Roth Capital, SVB Leerink LLC, and SVB Securities.
View the latest analyst ratings for RAIN.

What is the current price target for Rain Oncology?

9 Wall Street analysts have set twelve-month price targets for Rain Oncology in the last year. Their average twelve-month price target is $16.44, suggesting a possible upside of 88.2%. Citigroup Inc. has the highest price target set, predicting RAIN will reach $24.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $11.00 for Rain Oncology in the next year.
View the latest price targets for RAIN.

What is the current consensus analyst rating for Rain Oncology?

Rain Oncology currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RAIN will outperform the market and that investors should add to their positions of Rain Oncology.
View the latest ratings for RAIN.

What other companies compete with Rain Oncology?

Other companies that are similar to Rain Oncology include Design Therapeutics, BioVie, NGM Biopharmaceuticals, Marinus Pharmaceuticals and Phathom Pharmaceuticals. Learn More about companies similar to Rain Oncology.

How do I contact Rain Oncology's investor relations team?

The company's listed phone number is 510-953-5559 and its investor relations email address is [email protected] The official website for Rain Oncology is www.rainthera.com. Learn More about contacing Rain Oncology investor relations.